An Overview of the Laboratory Assay Systems and Reactives Used in the Diagnosis of Hepatitis C Virus (HCV) Infections by Recep Kesli
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
21 
An Overview of the Laboratory Assay Systems 
and Reactives Used in the Diagnosis of 
Hepatitis C Virus (HCV) Infections 
Recep Kesli 
Konya Education and Research Hospital, 
Department of Microbiology and Clinical Microbiology, Konya, 
Turkey 
1. Introduction 
In the mid-1970s, a new disease entity termed ‘non-A, non-B’ (NANB) hepatitis was first 
described and, in the following years, led to discovery of the causative virus, post-
transfusion, and to community-acquired NANB hepatitis increasingly becoming recognized 
as a potentially serious disease that results in liver cirrhosis and/or hepatocellular 
carcinoma.16, 26 Hepatitis C virus (HCV) was first identified in 1989 using molecular methods 
at the Chiron Corporation, but to date, the virus has never been visualized or grown in cell 
culture.37 Hepatitis C virus (HCV) is a single-stranded RNA virus with a genome of about 10 
000 nucleotides containing a single large, continuous open reading frame and with 
organization most closely resembling the Flaviviridae.11 HCV is a global healthcare problem 
and the World Health Organization (WHO) estimates that at least 170 million people (3 % of 
the world’s population) are infected with HCV worldwide and most of the patients are 
concentrated in developing countries. 48  
HCV Proteins. HCV proteins may be divided in two groups: Structural proteins and 
nonstructural proteins. Structural Proteins:  The nucleocapsid proteins (core), two envelope 
glycoproteins (E1 and E2), and a small transmembrane protein p7. E2 likely mediates cell 
entry by binding to one ore more specific cellular receptors or coreceptors, and has also been 
suggested to interact with and inhibit interferon-inducible protein kinase R (PKR).26 P7 may 
function as a viroporin. Non-structural proteins (NS): NS2, NS3, NS4 (A, B), NS 5 (A, B). 
NS2 may exist an E2p7NS2 processing intermediate due to inefficient signal peptidase 
cleavages at the E2-p7 and p7-NS2 junctions. NS2 has also been reported to 
coimmunoprecipitate. Other functions of NS2 are uncertain. NS3 has serine 
protease/helicase activity and a multifunctional protein. NS4A is associated with 
membranes. NS4B is important for RNA replication. It has a GTPase acitivity that is 
important RNA in replication. NS5B has RNA-depndent RNA polymerase activity resulting 
in initiating in-vitro RNA synthesis both primer dependent and independent. Anti-HCV 
reactives manufactured from these group of proteins. 4, 15, 35  
Organization of the HCV genome and polyprotein processing presented in Figure 1. 26 
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Fig. 1. Organization of the HCV genome and polyprotein.26 
2. Classification of laboratory assay systems and reactives used in the 
diagnosis of hepatitis C virus infection. 
Immunoasssay systems used in the diagnosis of hepatitis C virus infections may be divided 
into four groups. 
2.1. Anti-HCV assay. 
2.2. Strip immunblott assay (SIA). 
2.3. Hepatitis C virus core antigen assay. 
2.4. HCV RNA assay. 
Diagnostic tests used for the diagnosis of HCV infections may be divided into three groups 
according to aim of use. 22 
1. Screening test (Anti-HCV tests based on EIA or CIA) 
2. Supplemental test (Strip immunoblot assay-SIA) 
3. Confirmatory test (HCV RNA) (HCV Core Ag as a pre-confirmative test.).  
Detection or quantification of HCV RNA an important molecular assay based on the 
principle of target amplification used for confirming test results of immunoassay reactives. 
Reactives used in order to diagnose HCV infections also may be divided in to two groups 
according to identification method of the test. 32 
1. Indirect tests: (Anti-HCV and Strip immunoblot assays). 
www.intechopen.com
An Overview of the Laboratory Assay Systems and Reactives 
Used in the Diagnosis of Hepatitis C Virus (HCV) Infections 
 
341 
2. Direct tests: (HCV RNA, HCV Ag, HCV genotyping assays and sequencing of HCV 
genome). 
2.1 Anti-HCV assay 
Diagnostic procedures of hepatitis C virus infection in laboratories are principally based on 
the detection of antibodies (IgG) against recombinant HCV polypeptides by two main 
methods: Enzyme immunoassay (EIA) and Chemiluminescence immunoassay (CIA). The 
anti-HCV assay is used as a screening test. Non-structural and recombinant antigens have 
been used in the production of immunoassay reactives. Serologic and virologic markers of 
past or present HCV infection include IgG antibodies (anti-HCV). An assay for Ig M anti-
HCV is available, but it does not distinguish between acute and chronic HCV infection.25 
Three different generations of anti-HCV test kits have been developed to date. The first-
generation HCV enzyme immunoassay (EIA) detected only antibodies against the non-
structural region 4 (NS4) with recombinant antigen c100-3.25 With the development of second-
generation tests, additional antigens from the core region (c22-3), the NS3 region (c33c) and a 
part of c100-3 (named 5-1-1) from the NS4 region were used.17 The third-generation EIA anti-
HCV test used today includes an additional antigen from the NS5 region and a reconfiguration 
of the core and NS3 antigens.46 Anti-HCV assays have several disadvantages, such as a high 
rate of false positivity, a lack of sensitivity of detection in the early window periods of 45 to 68 
days after infection, the inability to distinguish between acute (ongoing active, viremic), past 
(recovered) and persistent (chronic) infections and a possibility of false negativity with 
samples from immmunocompromised patients who may not have an adequate antibody 
response.19, 30, 33, 36 Inorder to shorten the duration of the diagnosis of heaptitis C virus infection 
especially in preseroconversion period being capable of the detection of antibodies against NS 
5 proteins means that a third generation reactive is very important for anti-HCV assays. 
Because there remains a window period, estimated at 82 days with the second-generation 
assays, at 66 days with the third generation assays, between the infection and the detection of 
HCV antibodies 12. NS5, enables  the detection of HCV antibodies on an average of 26 days 
earlier in individuals with transfusion-transmitted HCV infection. Furthermore, sensitivity is 
also improved (approaching 97%), specifically in a high-prevalence population.14 
Summarized properties of the fully automated CIA based systems and anti-HCV reacitves 
shown in Table 1.  
2.2 Strip immunblot assay (SIA) 
SIA rectives used as supplementary test, involving recombinant immunblot assay (RIBA) HCV 
3.0 strip immunoassay (SIA) (Chiron Corporation, Emeryville, CA, USA), which contained 
recombinant antigens (c33c, NS5) and synthetic peptides (5-1-1, c100 and c22); and INNO-
LIA™ HCV Score (Innogenetics N. V. Ghent, Belgium) is a 3rd generation line immunoassay 
which incorporates HCV antigens derived from the core region, the E2 hypervariable region 
(HVR), the NS3 helicase region, the NS4A, NS4B, and NS5A regions. Both SIA’s are based on 
the principle of an enzyme immunoassay. Recombinant immunoblot assays are used as 
supplementary test of anti-HCV assays. As types of EIA, recombinant immunoblot assays also 
have several disadvantages, such as being difficult to perform, a high percentage of 
‘indeterminate’ results and a high cost. Therefore, these anti-HCV assays are not often used in 
developing countries or in routine diagnostic laboratory procedures. 23 
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Immunoassay 
Sytem 
Analytic method Test speed Anti-HCV 
reactive 
Abbott Arcihtect 
USA 
Chemiluminescent Microparticle
Immunoassay (CMIA) 
200 Test/h NS3, NS4.  
Abbott Axsyme Plus 
USA 
Microparticle Enzyme 
Immunoasay (MEIA) 
100 Test/h NS3, NS4, NS5.  
SeimensAdvia Centaur XP 
Germany 
Chemiluminescence (CHEM) 240 Test/h NS3, NS4, NS5.  
Seimens Advia Centaur CP
Germany 
Chemiluminescence (CHEM) 180 Test/h NS3, NS4, NS5. 
Roche Cobas e601 
Switzerland 
Electrochemiluminesans 
(ECLIA) 
170 Test/h NS3, NS4. 
Roche Cobas e411 
Switzerland 
Electrochemiluminescence 
(ECLIA) 
86 Test/h  NS3, NS4. 
Beckman Coulter UniCel 
DxI 600/800  
USA 
Chemiluminescence (CHEM) 200/400 
Test/h 
NS3, NS4. 
Beckman Coulter Access 2 
USA 
Chemiluminescence (CHEM) 100 Test/h NS3,NS4. 
Ortho-Clinical Diagnostics 
Vitros 3600 
USA 
Enhanced Chemiluminescence 
(ECHEM) 
189 Test/h NS3, NS4, NS5 
Ortho Clinical Diagnostics 
Vitros ECi/ECiQ 
USA  
Enhanced Chemiluminescence 
(ECHEM) 
90 Test/h NS3, NS4, NS5 
Diasorin Laison 
Italy 
Chemiluminescence (CHEM) 180 Test/h NS3, NS4, NS5 
Table 1. Summarized properties of CLIA based basic assay systems and reactives. 
2.3 Hepatitis C virus core antigen (HCV Ag) assay 
Total serum HCV core antigen, a surrogate marker of HCV replication, can also be detected 
and quantified. A commercial assay kit for it is available. HCV core antigen can be detected 
on average, 1 to 2 days after HCV RNA during the pre-seroconversion period. HCV Ag test 
is presented as a ‘’Direct marker for diagnosis of HCV infection’’. Sensitivity of HCV core 
antigen test is slightly lower than HCV RNA assay but many studies carried out with HCV 
core Ag test compared with HCV RNA, proved that the HCV Ag test is specific, 
reproducible, highly sensitive and clinically applicable assay. HCV antigen test also 
showing good correlation comparing with HCV RNA. HCV core antigen test may be used 
as a second line confirmatory test alternative to HCV RNA.23, 28, 29 It is also needed as a pre-
confirmatory test for anti-HCV results and to distinguish false positives from the accurate 
ones. This is because it is easy to perform, reliable, has a high specificity and sensitivity rate, 
is cost effective, is able to shorten the duration of the diagnosis of patients during the 
window period and has a lower risk of laboratory contamination than assays based on 
nucleic acid amplification technology. 45, 50 
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During the past decade, several HCV Ag tests have been developed as potential alternatives 
to HCV RNA assay. 5 The first was developed by Tanaka et al.45 1995, and then Aeyogi et al.1 
developed a new and 100-fold more sensitive test. In previous studies, the HCV Ag was 
detected one day after the HCV RNA in patients undergoing seroconversion. 12, 13, 34 The 
Architect HCV Ag assay (Abbott Laboratories, Diagnostics Division, Abbot Park, IL, USA) is 
highly specific, sensitive, reliable, easy to perform, reproducible, cost-effective and 
applicable as a screening, and pre-confirming test for anti-HCV assays in the laboratory 
procedures used for the diagnosis of hepatitis C virus infection. The Architect HCV Ag 
assay was performed using the automated Architect® i2000SR CIA system (Abbott 
Laboratories, Diagnostics Division, Abbot Park, IL, USA). The Architect HCV Ag assay is a 
two-step chemiluminescent microparticle immunoassay technology for the quantification of 
the HCV Ag in human serum or plasma samples. The sample volume required is 110 µl, and 
the total assay time is 36-40 min. The cutoff value is 3.00 fmol/liter (0.06 pg/mL); thus, 
values <3.00 fmol/l are considered nonreactive, values ≥3.00 fmol/l are considered reactive 
and values ≥3.00 fmol/l and <10.00 fmol/l are retested in duplicate. If both retest values are 
nonreactive, the specimen is considered nonreactive for HCV Ag. If one or both of the 
duplicates have a value ≥3.00 fmol/l, the specimen is considered repeatedly reactive. 29, 38  
2.4 Molecular diagnostic systems, and reactives used for the HCV RNA and HCV 
genotyping assays 
Confirmation test is needed. Although third-generation HCV reactives are more sensitive 
and specific than older generation assays, they still have a high percentage of false positive 
reactions, so that it is mandatory to confirm every reactivity, especially with low titers, by 
anti-HCV CIA or EIA with HCV RNA assay (reactives with a lower limit of detection of 50 
IU/mL or less) to avoid false positive results. To minimize the likelihood of false-positive 
anti-HCV results,  the CDC has recommended the confirmation of all anti-HCV results by 
either RIBA or HCV RNA assay.28, 29   
HCV RNA is the earliest marker of infection, and a direct indicator of ongoing viral 
replication. It appears 1 to 2 weeks after infection before any alterations in liver enzyme 
levels and appearance of anti-HCV antibodies can be detected. If the nucleic acid testing 
(NAT) result is positive, active HCV infection is confirmed. If NAT result is negative, the 
HCV antibody or infection status can not be determined. NAT assays are used to detect and 
quantify HCV RNA. 8, 18, 40 
HCV RNA assay systems can be divided into two groups: qualitative and quantitative HCV 
RNA.  
Qualitative HCV RNA assay. Target amplification methods used qualitative detection of 
HCV RNA and have lower limits of detection of 5-50 IU/mL: Reverse Transcriptase-PCR 
(single enzyme RT-PCR, dual enzyme RT-PCR, nested RT-PCR), TMA (transcription-
mediated amplification), NASBA (isothermal RNA amplification). This group includes the 
qualitative RT-PCR, of which the Amplicor™ HCV 2.0 (Roche Molecular Systems, USA) is 
an FDA- and CE-approved RT-PCR system for qualitative HCV RNA testing that allows 
detection of HCV RNA concentrations down to 50 IU/ml of all HCV genotypes. 31 
Transcription-mediated amplification- (TMA)-based qualitative HCV RNA detection has a 
very high sensitivity (lower limit of detection 5-10 IU/ml). 20, 41 Transcription Mediated 
Amplification (TMA) Component System, Versant™ HCV RNA Qualitative Assay (Siemens 
www.intechopen.com
 
Trends in Immunolabelled and Related Techniques 
 
344 
Healthcare Diagnostics, Germany) is also commercially available which is accredited by 
FDA and CE and provides an extremely high sensitivity, superior to RT-PCR-based 
qualitative HCV RNA detection assays. 21, 42, 43  
Quantitative HCV RNA assay. Quantification of HCV RNA can be determined by target 
amplification techniques Real-Time PCR assays), or by signal amplification methods 
(branched DNA- bDNA Assay). Several FDA- and CE-approved standardised systems are 
commercially available. The Cobas Amplicor™ HCV Monitor (Roche Diagnostics) is based 
on a competitive PCR technique whereas the Versant™  440 HCV RNA Assay (Siemens 
Healthcare Diagnostics) is based on a bDNA technique. Both have restricted lower limits of 
detection (500-615 IU/ml). More recently, the Cobas TaqMan assay and the Abbott 
RealTime™ HCV test, both based on real-time PCR technology, have been introduced and 
now replaced the qualitative and quantitative methods. All commercially available HCV 
RNA assays are calibrated to the WHO standard based on HCV genotype 1. It has been 
shown that results may vary significantly between assays with different HCV genotypes 
despite standardisation. 9, 47 
The Abbott RealTime™ HCV Test provides a lower limit of detection of 12 IU/mL, a 
specificity of more than 99.5 % and a linear amplification range from 12 to 10,000,000 IU/mL 
independent of the HCV genotype. 27, 39 VERSANT kPCR Molecular System Siemens 
Healthcare Diagnostics is also avialable as a real time PCR system for quantification of HCV 
RNA. Rotor Gene Q real time PCR device and Qiagen HCV RNA kits (Qiagen GmbH, 
Germany)  are used for quantification of HCV RNA by real time PCR method with 
specificity of 99.0 %, a lower limit of detection 34 IU/ml and capable to detect up to  10, 
000,000 IU/mL.  
In certain situations HCV RNA result can be negative in persons with active HCV infection. 
As the titre of anti-HCV increases during acute infection, the level of circulating HCV RNA 
declines; intermittent HCV RNA positivity has been observed among persons with chronic 
HCV infection. A negative HCV RNA result can also indicate resolved infection. Follow-up 
HCV RNA testing is indicated only in persons with serologically confirmed anti-HCV 
positive results. 8, 18 
Detection and quantification of HCV RNA is used as the only one confirmative test of all the 
anti-HCV, HCV Ag assays and SIA tests. The HCV RNA assay is a reliable method but 
needs technical skill and may also result in false positivity because of contamination. It is 
time consuming and expensive. 18, 38 HCV RNA is extensively used to confirm antibody-
based screening test results. Amplification methods (target amplification by RT-PCR, 
transmission-mediated amplification (TMA), and signal amplification by b-DNA-branch-
DNA are the most expensive methods (45-50 USD per test for real-time PCR, 10-12 USD per 
test for HCV Ag CIA, and 5-6 USD per test for anti-HCV CIA) when compared with anti-
HCV and HCV Ag tests; and require sophisticated technical equipment and highly trained 
personnel. One specific problem with the HCV RNA assay is that HCV RNA can be 
temporarily undetectable because of the transient, partial control of viral replication by the 
immune response. Patients in a period of non-viremia may be detected as anti-HCV-positive 
and HCV RNA-negative. In such a situation, the HCV RNA test should be repeated a few 
weeks later with a new sample. This need for re-testing is a disadvantage of the HCV RNA 
test. In addition, nucleic acid amplifications are time-consuming methods and have the risk 
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of laboratory contamination. for these reasons, amplification methods are not suitable for 
wide use in most laboratories, especially in developing countries. 2, 10, 24, 38, 44 
HCV Genotyping assay.  HCV has six genotypes represented by digits (1-6) and multiple 
subtypes represented by letters (a, b, c…) and most recently a seventh HCV genotype have 
been characterized. HCV genotyping should be carried out in every patient before antiviral 
therapy.6 Both direct sequence analysis and reverse hybridisation technology allow HCV 
genotyping. Reverse-hybridization method and kits (The VERSANT HCV Genotype Assay 
(LiPA Line Prob Assay) 2.0, Bayer HealthCare LLC, Tarrytown, NY, USA) also exist for 
hepatitis C virus genotype assay.  The test is mainly based on biotinylated DNA, generated by 
RT-PCR amplification of the 5’untranslated region (5’UTR) of HCV RNA, is hybiridized to 
immobilized oligonucleotide probes. The VersantTM HCV Genotype 2.0 System (Siemens 
Healthcare Diagnostics) is suitable for indentifying genotypes 1-6 and more than 15 different 
subtypes and is currently the preferred assay for HCV genotyping. By simultaneous analyses 
of the 5’UTR and core region, a high specificity is achieved especially to differentiate the 
genotype 1 subtypes (1a versus1b). The TruGene direct sequence assay determines the HCV 
genotype and subtype by direct analysis of the nucleotide sequence of the 5’UTR region. 
Incorrect genotyping rarely occurs with this assay. However, the accuracy of subtyping is 
poor. The current Abbott RealTime™ HCV Genotype II assay is based on real-time PCR 
technology, which is less time-consuming than direct sequencing. Preliminary data reveal a 
96% concordance at the genotype level and a 93% concordance on the genotype 1 subtype 
level when compared to direct sequencing of the NS5B and 5’UTR regions.  
Interpretation of HCV and acute hepatitis C test results  are presented in Tables 2 and 3.  
 
Immunoassay 
for anti-HCV 
Nucleic acid test 
for HCV RNA 
Supplemental test 
for anti-HCV 
Interpretation of HCV status 
Negative Not applicable Not applicable Never infected with HCV 
Positive Not done Not done Unknown, positive screening test 
needs confirmation 
Positive Positive Positive/not done Active HCV infection 
Positive Negative Not done Unknown, single negative HCV RNA 
result cannot determine infection 
status; perform RIBA to rule out 
screening test false-positive 
Positive Negative Positive Has been infected with HCV;repeat 
testing for HCV RNA to rule out 
active infection as HCV RNA levels 
may fluctuate 
Positive Not done Positive Has been infected with HCV; follow-
up testing for HCV RNA, liver 
enzymes is indicated to determine 
current infection status 
Positive Not done/ 
Negative 
Negative Never infected with HCV 
Table 2. Interpretation of HCV test results.26  
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Anti HCV1 HCV-RNA2 Interpretation 
Negative Negative Not acute hepatitis C 
Negative Positive Acute hepatitis C 
Positive Negative Probably not an acute hepatitis C* (retesting needed) 
Positive Positive Difficult to discriminate from chronic hepatitis C** 
1Third-generation EIA,  2HCV RNA assay with a lower limit of detection ≤50  IU/mL. 
*Generally seen in patients who have recovered from a past HCV infection. RIBA should be used. A 
positive RIBA with two or more HCV-RNA positive results suggest that HCV infection resolved. A 
negative RIBA result indicates the false positivity of the EIA result, in the both no further testing is 
needed. 
 **Acutely infected patients can also have HCV RNA and anti-HCV at the time of diagnosis. It is 
difficult in these cases to distinguish acute hepatitis C from an acute exacerbation of chronic hepatitis or 
acute hepatitis of another cause in a patient with chronic hepatitis C.  
Table 3. Interpretation of acute hepatitis C test results.8 
3. False positivity problem and reasons of false positive results of anti-HCV 
immunoassay reactives 
Although the present third generation EIA tests have better sensitivity and specifity rates 
than their predecessors, there still exists a high prevelance of false-positive results, 
especially among low risk group, immunocompromised patients or populations without 
liver diseases, leading to unnecessary cost-effective health expenditures and confusing 
diagnostic challenges. The most common problem in the laboratory screening assay of anti-
HCV is the false positivity of low titers.3, 7  
Among immunocompromised populations (e.g., hemodialysis patients) the average rate of 
false-positive results is approximately: 15 %. False positive anti-HCV results obtained from 
both CIA and EIA-based reactives can be explained by the fact that no structural antigens 
and proteins have been derived from HCV up to now. HCV has not been cultured and 
natural viral proteins are not available. Confirmatory test should be used in order to 
discriminate the false positive results from the accurate ones. 49 
3.1 Reasons of false results of anti-HCV immunoassay reactives. 
The amino acid sequence and the purity of the HCV antigen used for assay development are 
significant factors influencing both the specifity and the sensitivity of anti-HCV 
immunoassays. Because of the high IgG concentration in human blood (>5 mg/ml)-e.g. in 
paraproteinemia or auto-antibody production or after Ig G denaturation caused by repeated 
freezing and thawing or by heat-inactivation of serum samples , there is a strong tendency 
for some of the IgG molecules to be bound to the micro-well surface by direct adsorbtion or 
by indirect capture via the surface molecules, and then arouse a signal, giving false-positive 
results. This problem might be more serious when the samples are from patients with 
systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), portal cirrhosis, and some 
infectious diseases due to the very complicated, higher concentration of immunoglobulin 
components in their blood. 49 
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